Search Articles — Sudonull

https://sudonull.com/daraxonacib-for-pancreatic-cancer-risks-and-survival

The drug daraxonacib doubled survival in pancreatic cancer but does not cure. Learn about mechanisms, side effects, and real limits of the breakthrough. Read the analysis.

https://ymaho.com/breakthrough-technologies-in-oncology-shift-to-protac-and-car-t

Nature records a paradigm shift: oncology moves from inhibitors to PROTAC and cell therapy. Find out who wins in the new race and what awaits the market.

https://ymaho.com/lymphoma-metabolism-new-vulnerabilities-for-car-t-therapy

Nature reveals metabolic subtypes of DLBCL. Learn how glycolysis and lipid inhibitors enhance CAR-T efficacy. Read market forecast until 2028.

https://ymaho.com/oral-ebola-inhibitor-post-exposure-prophylaxis

We analyze what EMA actually recommended regarding the first oral drug against Ebola. Key facts, logistics, and forecasts. Read.

https://ymaho.com/ver-01-surpassed-opioids-for-chronic-pain-study

New cannabis-based pain inhibitor VER-01 showed better efficacy and tolerability than opioids for chronic back pain. Learn about the FDA breakthrough therapy of 2026.

https://ymaho.com/telitacicept-in-iga-nephropathy-phase-3-results-in-nejm

Interim Results of TELIGAN: Telitacicept Reduces Proteinuria by 58.9% vs 8.8% Placebo. Learn How the New Dual Inhibitor Is Changing the IgA Nephropathy Market.

https://ymaho.com/kras-g12c-colorectal-cancer-sotorasib-panitumumab-breakthrough

CodeBreak300 phase 3: Lumakras and Vectibix combination increased progression-free survival by 3 months. Treatment of KRAS G12C metastases approved. How dual blockade breaks 40-year resistance.

https://ymaho.com/crispr-in-vivo-reduces-cholesterol-by-60-in-verve-102-study

Single infusion of VERVE-201 sustainably lowers LDL by more than 60%. Learn how CRISPR editing is changing the hypercholesterolemia therapy market. Read the analysis.

https://ymaho.com/ema-approved-sma-gene-therapy-itvisma-and-a-drug-for-ms

European regulator recommended Itvisma for adults with SMA and Cenrifki for secondary progressive sclerosis. Learn how a one-time injection and a pill fill gaps in neurodegeneration treatment.

https://ymaho.com/fda-approved-vyvgart-for-all-serotypes-of-myasthenia-gravis

FDA approved efgartigimod (Vyvgart) for all serotypes of gMG, including seronegative patients. Learn how this will change the market and what it means for you. Read the detailed analysis.

https://ymaho.com/new-hiv-mechanism-penetration-into-resting-cells

Scientists have discovered how HIV-1 infects dormant immune cells via the CD4-LCK-CDK1 signaling pathway. This changes the approach to treatment and drug discovery. Read the breakthrough details.